Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

85.82 -4.68

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

84.68

Max

90.08

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.8% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.9B

15B

Vorige openingsprijs

90.5

Vorige sluitingsprijs

85.82

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jul 2026, 23:06 UTC

News

PepsiCo shares are lower in after-market hours following a downgrade to Hold by Citi, with the price target reduced to $145 from $170.

10 jul 2026, 23:01 UTC

News

Cognizant Technology Solutions received court approval for a $5.5 million settlement in a stockholder lawsuit, with shares trading higher in after-market hours.

10 jul 2026, 20:13 UTC

ETF Constituents
News
Correlated Moves

Vanguard Large-Cap ETF is trading lower in after-market hours, influenced by slight losses in top holdings META, AAPL, ABBV, MA, and NVDA.

10 jul 2026, 20:07 UTC

News
Correlated Moves

Ethereum is gaining as Circle Internet Group receives approval for a national trust bank, boosting interest in digital assets amid geopolitical tensions.

10 jul 2026, 20:07 UTC

News

Costco Wholesale shares are higher today, recovering from earlier losses despite concerns over moderating growth and sustainability amid easing fuel prices.

10 jul 2026, 20:07 UTC

News
Social Media

Micron Technology shares are lower amid a semiconductor sector selloff, despite announcing over $250 billion in U.S. investment for AI memory chips.

10 jul 2026, 20:07 UTC

News
Social Media
Event

Netflix Inc shares are lower amid concerns about declining subscriber engagement. The company is exploring strategies to enhance viewer interest, including live TV channels.

10 jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher as Circle Internet Group gains approval for a national trust bank focused on digital asset custody services. Ethereum also shows notable increases.

10 jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin is trading higher since Thursday's close, supported by Circle Internet Group's approval for a national trust bank focused on digital asset custody services.

10 jul 2026, 20:07 UTC

Correlated Moves
News

Ethereum is gaining amid increased market interest following Circle Internet Group's trust bank approval. Geopolitical tensions are also driving investors toward cryptocurrencies.

10 jul 2026, 20:06 UTC

News

Autodesk Inc shares are lower today following a negative report from StockStory, which advises avoiding the stock due to slower revenue growth and high payback periods.

10 jul 2026, 20:06 UTC

News

United Airlines shares are lower amid concerns following Delta's strong earnings report, which raised expectations for upcoming results but highlighted pricing power challenges.

10 jul 2026, 20:06 UTC

Correlated Moves
Social Media
News

Applied Materials shares advance as Needham raises price target to $740 and Stifel lifts its target to $650, reflecting strong demand in the semiconductor sector.

10 jul 2026, 20:03 UTC

News
Social Media

NVIDIA shares are higher today as Morgan Stanley reaffirms its Overweight rating and U.S. eases AI chip export curbs to the UAE.

10 jul 2026, 20:02 UTC

News

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

10 jul 2026, 20:02 UTC

News
Social Media

Fox Corp shares are higher, supported by record FIFA World Cup viewership and an upgrade to Buy from Rothschild Redburn, raising the price target to $71.

10 jul 2026, 20:01 UTC

News

Gilead Sciences is highlighted as a resilient dividend stock, yet shares are trading lower amid broader market volatility and recent declines.

10 jul 2026, 19:56 UTC

Social Media
News

Dollar Tree shares are higher after a positive UBS assessment, signaling an inflection point for the retailer amid cautious market sentiment ahead of key economic data.

10 jul 2026, 19:51 UTC

Social Media
News

Take-Two Interactive is under pressure amid sector weakness, with a recent report advising against the stock due to limited cash flow and declining sales projections.

10 jul 2026, 19:47 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Small-Cap ETF is lower amid ongoing geopolitical tensions and declines among key holdings, including SRPT, AXON, NTRA, LAMR, and IONS.

10 jul 2026, 19:47 UTC

News
Social Media

Tesla Inc's stock is higher, supported by increased buying interest and strong Model Y sales in China, with shares reaching an intraday high of $407.85.

10 jul 2026, 19:47 UTC

News

PayPal Holdings Inc is gaining momentum, driven by strong performance in Venmo and Braintree, alongside a clearer operational framework under CEO Dan Schulman.

10 jul 2026, 19:47 UTC

News
Social Media

Intel Corp's stock is lower as AMD's data center revenue outpaces Intel's, raising investor concerns amid ongoing profitability challenges.

10 jul 2026, 19:47 UTC

News

Qualcomm shares are lower at about $188.81 amid mixed options sentiment and a decline in implied volatility ahead of the upcoming earnings report.

10 jul 2026, 19:47 UTC

Correlated Moves
Social Media
News

Broadcom shares are lower despite a $30 billion agreement with Apple to produce custom silicon components through 2031, amid broader semiconductor industry concerns.

10 jul 2026, 19:46 UTC

News
Social Media

Rothschild Redburn upgraded Fox Corp to Buy, raising the price target to $71. The stock remains higher since Thursday's close despite earlier session pullbacks.

10 jul 2026, 19:46 UTC

News

American Airlines Group faces challenges ahead of its earnings report, with shares declining amid cautious sentiment following Delta Air Lines' strong Q2 performance.

10 jul 2026, 19:41 UTC

Macro News
ETF Constituents
News

FXI is trading higher following Shein's Hong Kong IPO approval, boosting confidence in Chinese equities. Key holdings XIACY and TCOM also show notable returns.

10 jul 2026, 19:36 UTC

News

CSX shares rise on TD Cowen, JP Morgan upgrades ahead of Q2 report.

10 jul 2026, 19:36 UTC

News
Social Media

Microsoft shares advanced after Argus reaffirmed a Buy rating, lowering the price target to $510. The stock remains near the upper end of its one-month range.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

17.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 106.22 USD  17.8%

Hoogste 157 USD

Laagste 82 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat